On July 27, 2025, Adaptimmune Therapeutics PLC announced it would sell its cell therapy assets for $55 million and potentially earn up to $30 million more based on future milestones, while also restructuring and significantly reducing its workforce by about 62%. This transaction includes plans for Adaptimmune to incur approximately $7-8 million in restructuring costs related to employee severance largely in Q3 2025.